# reload+after+2024-01-21 03:47:19.358790
address1§100 Overlook Center
address2§Suite 102
city§Princeton
state§NJ
zip§08540
country§United States
phone§609 375 2227
website§https://www.sonnetbio.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§Sonnet BioTherapeutics Holdings, Inc., a biotechnology company, owns a platform for biologic medicines of single or bifunctional action. The company develops fully human albumin binding technology, which utilizes human single chain antibodies fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. Its lead product candidate is SON-1010, a fully human single-chain version of interleukin 12 that is in Phase 1b/2a clinical trial for the treatment of solid tumor indications, including ovarian cancer, non-small cell lung cancer, and head and neck cancer. The company is also developing SON-080, a fully human version of interleukin 6, which is in Phase 1b/I2a clinical trail to treat chemotherapy-induced peripheral neuropathy and diabetic peripheral neuropathy; and SON-1210, a bispecific compound for solid tumor indications, including colorectal cancer. It has a license agreement with New Life Therapeutics Pte, LTD. to develop and commercialize pharmaceutical preparations containing a specific recombinant human interleukin-6. The company is headquartered in Princeton, New Jersey.
fullTimeEmployees§12
companyOfficers§[{'maxAge': 1, 'name': 'Dr. Pankaj  Mohan Ph.D.', 'age': 58, 'title': 'Founder, Chairman, CEO & President', 'yearBorn': 1965, 'fiscalYear': 2023, 'totalPay': 926996, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. John K. Cini Ph.D.', 'age': 70, 'title': 'Chief Scientific Officer & Co-Founder', 'yearBorn': 1953, 'fiscalYear': 2023, 'totalPay': 602480, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Jay  Cross', 'age': 53, 'title': 'Chief Financial Officer', 'yearBorn': 1970, 'fiscalYear': 2023, 'totalPay': 603420, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Donald J. Griffith CPA, CPA', 'age': 74, 'title': 'Controller & Director', 'yearBorn': 1949, 'fiscalYear': 2023, 'totalPay': 134048, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Susan  Dexter', 'age': 68, 'title': 'Chief Technical Officer', 'yearBorn': 1955, 'fiscalYear': 2023, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Richard T. Kenney FACP, M.D.', 'age': 65, 'title': 'Chief Medical Officer', 'yearBorn': 1958, 'fiscalYear': 2023, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Manuel  Dafonseca', 'title': 'Head of Clinical Operations', 'fiscalYear': 2023, 'exercisedValue': 0, 'unexercisedValue': 0}]
compensationAsOfEpochDate§1703980800
maxAge§86400
priceHint§4
payoutRatio§0.0
beta§0.973
priceToSalesTrailing12Months§31.771984
currency§USD
dateShortInterest§1702598400
forwardEps§-2.81
exchange§NCM
quoteType§EQUITY
shortName§Sonnet BioTherapeutics Holdings
longName§Sonnet BioTherapeutics Holdings, Inc.
firstTradeDateEpochUtc§1162305000
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§e0f4f091-b896-3bb3-bb50-c62febf22cab
gmtOffSetMilliseconds§-18000000
targetHighPrice§75.0
targetLowPrice§7.0
targetMeanPrice§36.75
targetMedianPrice§32.5
recommendationMean§1.5
recommendationKey§strong_buy
numberOfAnalystOpinions§4
quickRatio§0.554
grossMargins§0.0
ebitdaMargins§0.0
trailingPegRatio§None
